AMD currently affects approximately 10 million people in the US and is the leading cause of blindness in persons over age 65, according to an article published in the Journal of the American Medical Association.
The company says oral Z-monocys has successfully completed a six-month, 80-patient, randomized, double-blind clinical trial for the treatment of dry AMD.
In this trial, Z-monocys demonstrated statistically significant improvements in the major clinical features of dry AMD, including visual acuity, contrast sensitivity and photorecovery times, as compared to placebo.